Navigation Links
Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study

invisible">
Jill Pozarek
+1 212 830 2445
Edwin Valeriano
+1 212 830 2456
e-mail: investor.relations@novartis.com

'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
2. Tekturna, First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. New Data Show Xenical Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People
5. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
6. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
9. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
10. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
11. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
Post Your Comments:
(Date:12/1/2008)...d today announced the initiation of a Phase 1/2 cl... JAK2 inhibitor, in leading medical centers in Aus...ibrosis (CIMF). , , The trial is designed ...in patients with CIMF and is expected to enrol up ...l assess the safety profile and evaluate the pharm...
(Date:12/1/2008)...NB-0040 at Children,s Hospital, Health Sciences Ce...wswire/ -- Enobia Pharma, an emerging Canadian bio...ics for serious bone disorders, today announced th...m for hypophosphatasia was dosed. Enobia is invest...0040 for the treatment of this rare and often crip...
(Date:12/1/2008)... , ROCHESTER, Minn., Dec. 1 /PRNewswire-USNew...se of the drug therapy etanercept ineffective in t... of the liver caused by excessive consumption of a...the December issue of Gastroenterology ( http://... Additional audio and video resources, including e...
(Date:12/1/2008)...-FirstCall/ -- Following a,Request for Proposal i...sed,third generation smallpox vaccine, Public Wo...the Canadian Department of National Defence, has a...very of IMVAMUNE(R). , The Canadian authori...ntry,s bio-preparedness programme. , The co...
Breaking Medicine Technology:S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2324 1Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2324 2Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2324 3Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2324 4Human Genome Sciences to Sponsor Conference Call 2319 1Human Genome Sciences to Sponsor Conference Call 2319 2Tufts researchers update their food guide pyramid for older adults 8590 1Tufts researchers update their food guide pyramid for older adults 8590 2Tufts researchers update their food guide pyramid for older adults 8590 3Entrust Digital Signatures Help Secure More Than 18 Million U S ePassports 1682 1Entrust Digital Signatures Help Secure More Than 18 Million U S ePassports 1682 2Entrust Digital Signatures Help Secure More Than 18 Million U S ePassports 1682 3Entrust Digital Signatures Help Secure More Than 18 Million U S ePassports 1682 4
...URG, Germany, May 10th, 2007 - Antisense,Pharma, a...argeted,therapies for malignant tumors, today anno...12009 in high-grade glioma will be,presented at th...linical Oncology (ASCO), which will be held in Chi...he open-label, randomized dose-finding Phase,IIb-t...
...praisal Committee concludes that alteplase is clin... 14 May 2007 – A new clinical appraisal,publ...nical,Excellence (NICE) in the UK has recommended ... with acute ischaemic stroke, based on,its clinica...tive,care alone.1 Alteplase is marketed as Actilys...
Other Medicine Technology:2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 22007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 3Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 2Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 3Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 4Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 5
(Date:12/2/2008)...SANTA BARBARA, Calif., Dec. 2 Bio...g products and services, and Alere(R) , who provi..., productivity improvement and complex care manage...trophic conditions to health plans, employers, and... BioIQ,s home-test kits and online reporting tools...
(Date:12/2/2008)...LONDON, Dec. 2 Services form an in...turers, (OEMs,) revenues. It has therefore become,...edical imaging services,market to remain competit...tract penetration rates. , (Logo: http://... New analysis from Frost & Sullivan ( htt...
(Date:12/2/2008)... SPEAK to collect and dis... Bellevue, Wash. (PRWEB) Dece...nnounced the launch of a new initiative to focus p... awareness . The official kick-off of SPEAK will o...Pharmacists (ASHP) 2008 Midyear Clinical Meeting, ...
(Date:12/2/2008)... Xena Health and Solution...l Claims Service "Claims in a Cloud" as ...sgow and London (PRWEB) December 2, 2008 -- Making...s to the launch of the first phase of a "Cl... solution from Corporate Modelling partners Xena ...
Breaking Medicine News(10 mins):Health News:BioIQ and Alere to Provide At-Home Biometric Screening Tests to Employees 2Health News:Encouraging Prospects for Medical Imaging Equipment Services in Europe 2Health News:Encouraging Prospects for Medical Imaging Equipment Services in Europe 3Health News:Pharmacy OneSource Launches SPEAK Initiative to Promote Medication Safety Awareness 2Health News:Corporate Modelling Partners Start Selling BPM in Cloud Service 2
...holesterol can do to people. High-fat diets cause ...re looking at food labels // to know what they con... easier for consumers to avoid trans fats, which p...ked to an increased risk of heart disease, among o...
...e a greater risk of developing Alzheimer’s, the de...stralian researchers // has claimed. The researc...delphia and the Edith Cowan University in Western ...e 'almost certainly' increases risk from Alzheimer...
...y among the people of Queensland when it comes to ...okesman for Queensland Institute of Medical Resear...drive against skin cancer is not having the desire...MR did not elicit the expected number of responses...
...nd are seeking legal protection in the event of a ...n they would be compelled to work // under adverse...ety (OSH) regulations in force in the country are ... sued as per the law. This is very much likely w...
Other Medicine News:Health News:Food labels to include information on trans fats in US 2Health News:Food labels to include information on trans fats in US 3Health News:Obesity could lead to Alzheimer's 2
...iciency and quality to routine urine microscopic a...luorescent flow cytometry with fully automated uri...processing are easily accommodated by the rack-bas... high volume laboratories. Fluorescent flow cytom...
... is a single-use, disposable needle loading device... a Bard BrachyStar needle for interstitial seed im...on safety shield, inner compartment that holds see...lded fitting that connects the cartridge to the ne...
...System uses technology developed by Mortara, the c... digital Holter recorder in 1994. This true 12-lea...r study provides superior ST segment analysis. ,...l recorder allows a full 24-hour 12-lead study to ...
Data review and analysis is carried out with the Acquidata Uromac software already supplied with Acquidata Uromac Lab based urodynamics systems
Medicine Products: